Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine.

Wahome N, Pfeiffer T, Ambiel I, Yang Y, Keppler OT, Bosch V, Burkhard P.

Chem Biol Drug Des. 2012 Sep;80(3):349-57. doi: 10.1111/j.1747-0285.2012.01423.x. Epub 2012 Jul 3.

PMID:
22650354
2.

N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.

Li D, Liu J, Zhang L, Xu T, Chen J, Wang L, Zhao Q.

Virol Sin. 2015 Dec;30(6):449-56. doi: 10.1007/s12250-015-3664-6. Epub 2015 Dec 21.

PMID:
26715302
3.

Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.

Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR.

AIDS. 2009 Oct 23;23(16):2069-77. doi: 10.1097/QAD.0b013e32832faea5.

PMID:
19710597
4.

Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.

Maeso R, Huarte N, Julien JP, Kunert R, Pai EF, Nieva JL.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):863-76. doi: 10.1089/AID.2010.0265. Epub 2011 Jan 15.

PMID:
21142698
6.

Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC Jr.

Clin Vaccine Immunol. 2014 Aug;21(8):1086-93. doi: 10.1128/CVI.00320-14. Epub 2014 May 28.

7.

Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.

Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R.

Virology. 2008 Mar 30;373(1):72-84. Epub 2007 Dec 26.

8.

Characterization of a trimeric MPER containing HIV-1 gp41 antigen.

Hinz A, Schoehn G, Quendler H, Hulsik DL, Stiegler G, Katinger H, Seaman MS, Montefiori D, Weissenhorn W.

Virology. 2009 Aug 1;390(2):221-7. doi: 10.1016/j.virol.2009.05.015. Epub 2009 Jun 18.

9.

Multiple antigen peptide mimetics containing gp41 membrane-proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs.

Zhang L, Miao L, Gong X, Zhang H, Yang L, Shi Y, Kong W, Jiang C, Shan Y.

J Pept Sci. 2013 Aug;19(8):491-8. doi: 10.1002/psc.2526. Epub 2013 Jun 21.

PMID:
23794478
10.
11.

The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.

Huarte N, Lorizate M, Maeso R, Kunert R, Arranz R, Valpuesta JM, Nieva JL.

J Virol. 2008 Sep;82(18):8986-96. doi: 10.1128/JVI.00846-08. Epub 2008 Jul 2.

12.

Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery.

Mühle M, Hoffmann K, Löchelt M, Denner J.

Immunol Res. 2013 May;56(1):61-72. doi: 10.1007/s12026-013-8387-x.

PMID:
23440699
13.

Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.

Benen TD, Tonks P, Kliche A, Kapzan R, Heeney JL, Wagner R.

J Biomed Sci. 2014 Aug 27;21:79. doi: 10.1186/s12929-014-0079-x.

14.

Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.

Guenaga J, Wyatt RT.

PLoS Pathog. 2012;8(7):e1002806. doi: 10.1371/journal.ppat.1002806. Epub 2012 Jul 19.

15.

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.

Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, Compans RW, Yang C.

PLoS One. 2011;6(5):e14813. doi: 10.1371/journal.pone.0014813. Epub 2011 May 19.

16.

A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.

Lai RP, Hock M, Radzimanowski J, Tonks P, Hulsik DL, Effantin G, Seilly DJ, Dreja H, Kliche A, Wagner R, Barnett SW, Tumba N, Morris L, LaBranche CC, Montefiori DC, Seaman MS, Heeney JL, Weissenhorn W.

J Biol Chem. 2014 Oct 24;289(43):29912-26. doi: 10.1074/jbc.M114.569566. Epub 2014 Aug 26.

17.

Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.

Zhai Y, Zhong Z, Zariffard M, Spear GT, Qiao L.

Vaccine. 2013 Nov 4;31(46):5422-9. doi: 10.1016/j.vaccine.2013.09.003. Epub 2013 Sep 19.

18.

Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Dieltjens T, Heyndrickx L, Willems B, Gray E, Van Nieuwenhove L, Grupping K, Vanham G, Janssens W.

Retrovirology. 2009 Dec 14;6:113. doi: 10.1186/1742-4690-6-113.

19.

Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.

Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, Tsai S, Julien JP, Hessell AJ, Wang S, Lu S, Burton DR, Pai EF, Degrado WF, Scott JK.

J Virol. 2012 Mar;86(6):2930-41. doi: 10.1128/JVI.06349-11. Epub 2012 Jan 11.

20.

Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Diomede L, Nyoka S, Pastori C, Scotti L, Zambon A, Sherman G, Gray CM, Sarzotti-Kelsoe M, Lopalco L.

J Virol. 2012 Apr;86(8):4129-38. doi: 10.1128/JVI.06359-11. Epub 2012 Feb 1.

Supplemental Content

Support Center